Segantii Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Segantii Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-32,950	Closed	-$6.31M	–	94
2023 Q4	$6.31M	Buy	32,950 +13,700	+71%	+$2.33M	0.33%	60
2023 Q3	$3.41M	Sell	19,250 -9,550	-33%	-$1.82M	0.12%	72
2023 Q2	$5.47M	Buy	+28,800	New	+$5.71M	0.29%	60
2019 Q3	–	Sell	-98,000	Closed	-$7.11M	–	72
2019 Q2	$7.11M	Buy	+98,000	New	+$7.52M	0.63%	25
2017 Q2	–	Sell	-500	Closed	-$26K	–	70
2017 Q1	$26K	Buy	+500	New	+$23.1K	﹤0.01%	351

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Segantii Capital Management's ALNY Position: Q1 2024 in Review

Segantii Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 32,950 shares — an estimated $6.31M sold.

Segantii Capital Management first reported a position in ALNY in Q1 2017 and held it in 5 quarters. The position peaked at $7.11M in Q2 2019. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

Segantii Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Segantii Capital Management sold 32,950 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $6.31M.
Segantii Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Segantii Capital Management's Alnylam Pharmaceuticals position peaked at $7.11M in Q2 2019.
498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Segantii Capital Management's 13F filing for Q1 2024, filed 14 May 2024.